David H. Gutmann, MD, MS, PhD

Washington University in St. Louis (WU)

For the past 25 years, our preclinical and clinical research efforts aim to define the genomic, genetic, cellular and molecular determinants that cause nervous system dysfunction in people with neurogenetic disorders, like neurofibromatosis type 1 (NF1), using a combination of novel genetically engineered mice and human induced pluripotent stem cells. The goal of our work is not only to establish new treatments for individuals with NF1, but also to better understand similar medical problems in the general population. Moreover, as a neurologist who cares for children and adults with NF1, Dr. Gutmann seeks to identify the factors that underlie nervous system disease heterogeneity relevant to the implementation of precision (personalized) medicine strategies.

Additional information can be found on the Gutmann Laboratory Website (https://gutmannlab.wustl.edu/) as well as on the Neurofibromatosis Center Website (https://nfcenter.wustl.edu/).